Related Experiment Video
Updated: Jul 20, 2026

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells
Published on: March 1, 2024
Regulation of ERK3/MAPK6 expression by BRAF
Klaus P Hoeflich1, Michael T Eby, William F Forrest
1Department of Molecular Biology, Genentech, South San Francisco, CA 94080, USA.
Abstract:
Several forms of cancer are characterized by frequent activating mutations in the serine/threonine kinase, BRAF. Substitution of glutamic acid for valine at codon 600 (V600E) accounts for approximately 90% of all BRAF activating mutations and leads to stimulation of kinase activity, downstream signaling, and cell transformation. To better understand the molecular pathogenesis induced by oncogenic BRAF signaling, we used microarray gene expression profiling to comprehensively analyze the BRAF-directed transcriptional program of cells expressing a conditionally active form of BRAFV600E. Several novel genes that affect proliferation, cell survival, angiogenesis and immune surveillance were identified as possible mediators of BRAF-induced oncogenic signaling. Moreover, we show that a MAPK family member, extracellular signal-regulated kinase-3 (ERK3/MAPK6) is highly expressed in response to BRAF signaling in this system. Cellular ERK3 protein is highly unstable and pharmacological inhibition of BRAF activity resulted in rapid ERK3 degradation. In melanoma cells, RNAi-mediated knockdown of endogenous BRAF or treatment with MEK inhibitors that prevent ERK1/2 activation led to a reduction in ERK3 levels, indicating that elevated ERK3 expression is mediated through MEK1/2 signaling. These results provide strong evidence for another mode by which BRAF can regulate the ERK protein kinase family and suggest ERK3 to be a potential pharmacodynamic marker for targeting BRAF signaling in melanoma.
Insights
Activating BRAF mutations drive cancer. This study identifies novel genes regulated by BRAF signaling, including extracellular signal-regulated kinase-3 (ERK3), a potential marker for BRAF-targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Activating mutations in the serine/threonine kinase BRAF, particularly the BRAF V600E mutation, are common in various cancers.
- These mutations lead to increased kinase activity, aberrant downstream signaling, and cellular transformation, driving oncogenesis.
Purpose of the Study:
- To comprehensively analyze the transcriptional program regulated by oncogenic BRAF signaling.
- To identify novel genes involved in BRAF-mediated oncogenesis.
- To investigate the role of extracellular signal-regulated kinase-3 (ERK3/MAPK6) in BRAF-driven signaling.
Main Methods:
- Microarray gene expression profiling of cells with conditionally active BRAF V600E.
- Analysis of novel gene expression changes.
- Investigation of ERK3 protein stability and regulation.
- RNA interference (RNAi) mediated knockdown of BRAF and MEK inhibitor treatment in melanoma cells.
Main Results:
- Identified novel genes influencing proliferation, cell survival, angiogenesis, and immune surveillance as mediators of BRAF oncogenic signaling.
- Demonstrated high expression of extracellular signal-regulated kinase-3 (ERK3/MAPK6) in response to BRAF signaling.
- Showed that BRAF inhibition leads to rapid ERK3 degradation.
- Confirmed that elevated ERK3 expression is mediated through MEK1/2 signaling in melanoma cells.
Conclusions:
- BRAF signaling regulates a distinct transcriptional program involving novel oncogenic mediators.
- Extracellular signal-regulated kinase-3 (ERK3) is a novel downstream target of BRAF/MEK signaling.
- ERK3 represents a potential pharmacodynamic marker for monitoring BRAF-targeted therapies in melanoma.
Related Concept Videos
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
Master Transcription Regulators
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway

